Alterations in Gene and Protein Expression of Cannabinoid CB2 and GPR55 Receptors in the Dorsolateral Prefrontal Cortex of Suicide Victims

被引:0
作者
María S. García-Gutiérrez
Francisco Navarrete
Gemma Navarro
Irene Reyes-Resina
Rafael Franco
Jose Luis Lanciego
Salvador Giner
Jorge Manzanares
机构
[1] Universidad Miguel Hernandez—CSIC,Instituto de Neurociencias de Alicante
[2] Instituto de Salud Carlos III,Red Nacional de Trastornos Adictivos
[3] Ministerio de Economía y Competitividad y Fondo de Desarrollo Regional Europeo,Departamento de Bioquímica y Biología Molecular, Facultad de Biología
[4] Universidad de Barcelona,Centro de Investigación Biológica en Red para enfermedades neurodegenerativas (CIBERNED)
[5] Instituto de Salud Carlos III,Departamento de Neurociencias, Centro de Investigación Médica Aplicada (CIMA)
[6] Universidad de Navarra,undefined
[7] Instituto de Medicina Legal,undefined
来源
Neurotherapeutics | 2018年 / 15卷
关键词
CB; r; GPR55; Suicide; Dorsolateral prefrontal cortex; Gene expression; In situ proximity ligation assay;
D O I
暂无
中图分类号
学科分类号
摘要
Recent studies point to the cannabinoid CB2 receptors (CB2r) and the non-cannabinoid receptor GPR55 as potential key targets involved in the response to stress, anxiety, and depression. Considering the close relationship between neuropsychiatric disorders and suicide, the purpose of this study was to evaluate the potential alterations of CB2r and GPR55 in suicide victims. We analyzed gene and protein expression of both receptors by real-time PCR and western blot, respectively, in the dorsolateral prefrontal cortex (DLPFC) of 18 suicide victims with no clinical psychiatric history or treatment with anxiolytics or antidepressants, and 15 corresponding controls. We used in situ proximity ligation assay to evaluate whether the receptors formed heteromeric complexes and to determine the expression level of these heteromers, also assessing the co-expression of heteromers in neurons, astroglia, or microglia cells. CB2r and GPR55 gene expressions were significantly lower (by 33 and 41%, respectively) in the DLPFC of suicide cases. CB2r protein expression was higher, as were CB2-GPR55 heteroreceptor complexes. The results also revealed the presence of CB2-GPR55 receptor heteromers in both neurons and astrocytes, whereas microglial cells showed no expression. We did not observe any significant alterations of GPR55 protein expression. Additional studies will be necessary to evaluate if these alterations are reproducible in suicide victims diagnosed with different psychiatric disorders. Taken together, the results suggest that CB2r and GPR55 may play a relevant role in the neurobiology of suicide.
引用
收藏
页码:796 / 806
页数:10
相关论文
共 183 条
[1]  
Furczyk K(2013)The neurobiology of suicide—a review of post-mortem studies Journal of molecular psychiatry 1 2-71
[2]  
Schutova B(2015)An overview of the neurobiology of suicidal behaviors as one meta-system Molecular psychiatry 20 56-816
[3]  
Michel TM(2014)The molecular bases of the suicidal brain Nature reviews 15 802-583
[4]  
Thome J(1991)Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study J Neurosci 11 563-208
[5]  
Buttner A(2008)Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice The pharmacogenomics journal 8 196-973
[6]  
Sokolowski M(2004)Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors Neuropharmacology 46 966-1581
[7]  
Wasserman J(2007)Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function Endocrinology 148 1574-572
[8]  
Wasserman D(2008)BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice J Neurochem 105 565-582
[9]  
Turecki G(2003)Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice Behav Pharmacol 14 573-553
[10]  
Herkenham M(2003)The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions Br J Pharmacol 138 544-617